Alzheimer’s disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease’s progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer’s disease.
Emerging Drugs and Targets for Alzheimer’s Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer’s drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts, these volumes are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.
Table of Content
Neuronal Plasticity as target; Chapter 15: Regeneration of Degenerated Brain: A Promising Therapeutic Target; Chapter 16: Promoting synaptic resilience in AD patients through PDE inhibition; Chapter 17: A new generation of non invasive NGF-based therapies for Alzheimer’s disease; Chapter 18: Possible clinical applications of stem cell strategies in AD therapies; Neuronal protection as target; Chapter 19: Targeting Oxidative Mechanisms in Alzheimer Disease; Chapter 20: Davunetide (NAP) Pharmacology: Neuroprotection and tau; Chapter 21: Targeting NF- B inflammatory and pro-survival signaling in AD; Chapter 22: PPAR in Alzheimer`s disease; Miscellaneous targets and strategies; Chapter 23: Serotonin 5-HT4 receptors as pharmacological targets for the treatment of Alzheimer¦s disease; Chapter 24: Liver X Receptors as potential therapeutic target for AD; Chapter 25: Discovery of memoquin, a multi-target-directed ligand for the treatment of Alzheimer’s disease; Chapter 26: RNA interference of genes related to AD; Chapter 27: Medicinal plants, phytochemicals and Alzheimer’s Disease
More ebooks from the same author(s) / Editor
11,806 Ebooks in this category
